Updated:
NovelStem International Corp.
Jay Belle Isle runs NovelStem International, a public biotech shell with no operating revenue and a going-concern warning as of 2024.
NovelStem International Corp.
NovelStem International Corp. trades on the OTC markets from a corporate address in Boca Raton, Florida. The company was originally incorporated as First Hartford Corp. in the 1990s and operated as a real estate developer before pivoting, through a series of reverse mergers, into biotechnology. Jay W. Belle Isle serves as President, CEO, and CFO — a consolidation of authority typical of microcap shells. The firm has described its mission as commercializing stem-cell technologies, but has not disclosed any clinical-trial data, regulatory approvals, or material licensing agreements. In SEC filings, NovelStem states it holds an indirect equity interest in a Chinese stem-cell company and a minority stake in a U.S.-based manufacturer of synthetic diamonds. Neither holding has generated reported revenue for NovelStem. The firm has not disclosed any direct investments, co-investment vehicles, or fund structures. Its geographic footprint is limited to administrative presence in Florida and legacy minority positions in China and New Jersey. The company's public float has historically been used as a vehicle for convertible-debt financing rather than operating income. As of May 2025, NovelStem reported zero full-time employees beyond its named officers. The firm maintains no independent website beyond a single landing page and has no LinkedIn presence. Total assets were reported at under $1 million in its most recent quarterly filing. The company has no known philanthropic foundations, operating businesses, or subscription pools alongside its corporate structure. In August 2024, NovelStem filed a Form 10-K that included a going-concern warning from its auditor. NovelStem's structural posture is a publicly listed corporate entity with no operations — a shell that provides liquidity and reverse-merger access for private companies seeking public-market entry. This distinguishes it from operating family offices and venture firms that deploy capital actively. The concentration of C-suite roles under a single officer and the reliance on convertible instruments reflects a governance model common among OTC-listed shells.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boca Raton
Corporate office
Boca Raton, FL, United States
Principals
Jay W. Belle Isle
President, Chief Executive Officer, Chief Financial Officer
Sector focus
Frequently asked questions
Does NovelStem International have any commercialized stem-cell products?
No. The company has not disclosed any clinical trials, FDA approvals, or commercialized medical products. Its SEC filings describe only indirect, non-controlling equity stakes in affiliated entities that themselves have not generated reported revenue for NovelStem.
Who makes investment decisions at NovelStem International?
Jay W. Belle Isle serves simultaneously as President, CEO, and CFO, per SEC filings. No investment committee or separate chief investment officer has been disclosed. The firm's transactions are corporate-level decisions executed by Mr. Belle Isle.
How does NovelStem International source its portfolio holdings?
The company has not described a deal-sourcing process. Its two known minority holdings — in a Chinese stem-cell affiliate and a New Jersey-based synthetic-diamond manufacturer — were acquired through share exchanges rather than traditional venture deal flow or auction processes.
Why does NovelStem International trade publicly if it has no operating revenue?
OTC-listed shells like NovelStem provide a regulatory vehicle for private companies seeking to go public through a reverse merger. The public listing itself is the asset — it offers liquidity, SEC reporting infrastructure, and capital-market access that a private operating company may lack.
What does NovelStem International's auditor say about the firm's viability?
In the August 2024 Form 10-K, NovelStem's independent auditor included a going-concern explanatory paragraph, noting that the company's lack of revenue and dependence on external financing raise substantial doubt about its ability to continue as a going concern.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: